Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project)

Rheumatology

Volumn 43, Issue 11, 2004, Pages 1374-1382

  Hallert, E ^a,b   Husberg, M ^b   Jonsson, D ^b   Skogh, Thomas ^a,b  

^a ÖREBRO UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cost of Illness; Direct costs; Early rheumatoid arthritis; Indirect costs; Outcome

Indexed keywords

ANALGESIC AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; IMMUNOGLOBULIN M; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR;

ABSENTEEISM; ADULT; AGE DISTRIBUTION; AGED; ALTERNATIVE MEDICINE; AMBULATORY CARE; ARTICLE; CALCULATION; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG COST; FEMALE; HAND FUNCTION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SWEDEN; WORK DISABILITY;

ADULT; AGED; ARTHRITIS, RHEUMATOID; COMPLEMENTARY THERAPIES; COST OF ILLNESS; DISABILITY EVALUATION; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HEALTH STATUS INDICATORS; HOSPITAL COSTS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; SICK LEAVE; SWEDEN;

EID: 4944221371     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh324     Document Type: Article

References (42)

1. Yelin E, Callahan L. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum 1995;38: 1351-62.
2. Sokka T, Krishnan E, Häkkinen A, Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum 2003;48:59-63.
3. Sokka T, Pincus T. Markers for work disability in rheumatoid arthritis. J Rheumatol 2001;28:1718-22.
4. Albers JMC, Kuper HH, van Riel PLCM et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology 1999;38:423-30.
5. Van Jaarsveld CHM, Jacobs JWG, Schrijvers AJP, Heurkens AHM, Haanen HCM, Bijlsma JWJ. Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br J Rheumatol 1998;37:837-47.
6. Jonsson D, Husberg M. Socioeconomic costs of rheumatic diseases: implications for technology assessment. Int J Technol Assess Health Care 2000;16:1193-2000.
7. Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis: a patient-oriented study of chronic disease costs. Arthritis Rheum 1987;21:827-33.
8. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986;29:488-93.
9. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
10. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol 1997;24:719-25.
11. Newhall-Perry K, Law NJ, Ramos B et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. J Rheumatol 2000;27:1156-63.
12. Söderlin M, Kautiainen H, Jonsson D, Skogh T, Leirisalo-Repo M. The costs of early inflammatory joint disease: a population-based study in Southern Sweden. Scand J Rheumatol 2003;32:216-24.
13. Lapsley HM, March LM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM. Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis 2002;61: 818-21.
14. Merkesdal S, Roof J, Schöffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001;44:528-34.
15. Hallert E, Thyberg I, Hass U, Skargren E, Skogh T. Comparison between women and men with recent-onset rheumatoid arthritis regarding disease activity and functional ability over two years (the TIRA project). Ann Rheum Dis 2003;62:667-70.
16. Arnett FC, Edworthy SM, Blich DA et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, Van de Putte LBA, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995;38:44-8.
18. Eberhardt KB, Svensson B, Moritz U. Functional assessment of early rheumatoid arthritis. Br J Rheumatol 1988;27:364-71.
19. Ekdahl C, Eberhardt KB, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Scand J Rheumatol 1998;17:263-71.
20. Federation of Swedish County Councils (Landstingsförbundet). Stockholm.
21. Serden L, Lindquist R, Rosen M. Have DRG-based prospective payment systems influenced the number of secondary diagnoses in health care administrative data? Health Policy. 2003;65:101-17.
22. Dougados M, Smolen JS. Pharmacological management of early rheumatoid arthritis, does combination therapy improve outcomes? J Rheumatol 2002;66(Suppl):20-6.
23. Verstappen SM, Jacobs JW, Bijlsma JW et al. Five-year follow-up of rheumatoid arthritis patients after early treatment with disease modifying antirheumatic drugs. Arthritis Rheum 2003;48:1797-807.
24. Kalden JR. Expanding role of biologic agents in rheumatoid arthritis. J Rheumatol 2002;66(Suppl):27-37.
25. Lubeck DP. The economic impact of arthritis. Arthritis Care Res 1995;4:304-10.
26. Liang MH, Larson M, Thompson M et al. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984; 27:522-9.
27. Lajas C, Abasölö L, Bellajdel B et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003;49:64-70.
28. Yelin E. The costs of rheumatoid arthritis - absolute, incremental and marginal estimates. J Rheumatol 1996;23:47-51.
29. Jacobs J, Keyserling JA, Britton M, Morgan GJ Jr, Wilkenfield J, Hutchings HC. The total care and the use of pharmaceuticals in the management of rheumatoid arthritis: the Medi_Cal program. J Clin Epidemiol 1988;41:215-23.
30. Lanes SF, Lanza LL, Radensky PW et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting - the importance of drug and surgery costs. Arthritis Rheum 1997;40:1475-81.
31. Jonsson B, Rehnberg C, Borgquist L, Larsson SE. Locomotion status and costs in destructive rheumatoid arthritis - a comprehensive study of 82 patients from a population of 13 000. Acta Ortop Scand 1992; 63:207-12.
32. Cooper NJ, Mugford M, Symmons DPM, Barett EM, Scott DGI. Total costs and predictors of costs in individuals with early inflammatory polyarthritis: a community-based prospective study. Rheumatol 2002;41:767-74.
33. Clarke AE, Zowall H, Levinton C et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997;24:1051-60.
34. Prashker MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis. Arthritis Rheum 1995;38:318-25.
35. Buchbinder R, Gingold Hall S, Cohen M. Non-prescription complementary treatments used by rheumatoid arthritis patients attending a community-based rheumatology practice. Int Med J 2002;32:208-14.
36. Leardini G, Salaffi F, Montanelli R, Gerzeli S, Canesi B. A multicentre cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol 2002;20:505-15.
37. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996;35:781-90.
38. Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis. Arthritis Rheum 2002;46: 2310-19.
39. Clarke AE, Levinton C, Joseph L et al. Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis. J Rheumatol 1999;26:1068-75.
40. Yelin E, Wanke L. An assessment of the annual and long-term direct costs of rheumatoid arthritis. Arthritis Rheum 1999;42:1209-18.
41. Singh G, Terry D, Ramey D, Wolfe F, Fries J. Long-term medical costs and outcomes are significantly associated with early changes in disability in rheumatoid arthritis [abstract]. Arthritis Rheum 1996;39(Suppl):S318.
42. Ruof J, Hulsemann JL, Mittendorf T et al. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources. Ann Rheum Dis 2003;62:544-50.